Phase 1/2, multicenter, non-randomized, open-label, multiple-dose first-in-human study of U3-1402 (anti-HER3 antibody drug conjugate) in subjects with HER3-positive metastatic breast cancer

被引：4

作者：

Kogawa, Takahiro

Yonemori, Kan

Naito, Yoichi

Noguchi, Emi

Shimizu, Chikako

Tamura, Kenji

Hosono, Ako

Matsubara, Nobuaki

Sugihara, Masahiro

Ogawa, Hayao

Majima, Shuji

Yu, Channing

Ueno, Suguru

Takano, Toshimi

机构：

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.TPS1116

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS1116

引用

页数：5

共 50 条

[21] Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer [J].

Krop, Ian E. ;

Beeram, Muralidhar ;

Modi, Shanu ;

Jones, Suzanne F. ;

Holden, Scott N. ;

Yu, Wei ;

Girish, Sandhya ;

Tibbitts, Jay ;

Yi, Joo-Hee ;

Sliwkowski, Mark X. ;

Jacobson, Fred ;

Lutzker, Stuart G. ;

Burris, Howard A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) :2698-2704

[22] Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). [J].

Krop, Ian E. ;

Masuda, Norikazu ;

Mukohara, Toru ;

Takahashi, Shunji ;

Nakayama, Takahiro ;

Inoue, Kenichi ;

Iwata, Hiroji ;

Toyama, Tatsuya ;

Yamamoto, Yutaka ;

Hansra, Damien Mikael ;

Takahashi, Masato ;

Osaki, Akihiko ;

Koyama, Kumiko ;

Inoue, Tatsuya ;

Yonekura, Takatoshi ;

Mostillo, Joseph ;

Ohwada, Shoichi ;

Tanaka, Yoshimi ;

Sternberg, David W. ;

Yonemori, Kan .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)

[23] First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer. [J].

Park, Yeon Hee ;

Ahn, Hee Kyung ;

Kim, Ji-Yeon ;

Ahn, Jin Seok ;

Im, Young-Hyuck ;

Kim, Seol-Hee ;

Lee, Sunbae ;

Chung, Hye-Shin ;

Park, Soon Jae .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

[24] Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation [J].

Goetz, Matthew P. ;

Wander, Seth Andrew ;

Bachelot, Thomas ;

Batist, Gerald ;

Cortes, Javier ;

Cristofanilli, Massimo ;

Curigliano, Giuseppe ;

De Nonneville, Alexandre ;

Gal-Yam, Einav Nili ;

Jhaveri, Komal L. ;

Ma, Cynthia X. ;

Parsons, Heather Anne ;

Rugo, Hope S. ;

Sammons, Sarah L. ;

Stover, Daniel G. ;

Twelves, Chris ;

Bardia, Aditya ;

Plourde, Paul V. ;

Portman, David Jay ;

Damodaran, Senthil .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[25] SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study [J].

Li, Ziming ;

Song, Zhengbo ;

Hong, Wei ;

Yang, Nong ;

Wang, Yongsheng ;

Jian, Hong ;

Liang, Zibin ;

Hu, Sheng ;

Peng, Min ;

Yu, Yan ;

Wang, Yan ;

Jiao, Zicong ;

Zhao, Kaijing ;

Song, Ke ;

Li, You ;

Shi, Wei ;

Lu, Shun .

SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)

[26] An open-label, multicenter, phase 2 study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), in previously treated patients with HER2-positive (HER2+) or HER2-low unresectable or metastatic breast cancer (BC) [J].

Bardia, Aditya ;

O'Sullivan, Ciara Catherine ;

Mahtani, Reshma L. ;

Blau, Sibel ;

Abdulla, Nihal E. ;

Ali, Azka ;

Bansal, Rani ;

Meyer, Janelle Marie ;

George, Mridula Annette ;

Han, Hyo S. ;

Pluard, Timothy J. ;

Papish, Steven W. ;

Jones, Jason Michael ;

Rong, Yuanxin ;

Gao, Guozhi ;

Rugo, Hope S. .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[27] A phase 2, multicenter, open-label study of trastuzumab deruxtecan (DS-8201a) in subjects with HER2-positive, unresectable and/or metastatic breast cancer previously treated with T-DM1. [J].

Baselga, Jose ;

Tamura, Kenji ;

Yamashita, Toshinari ;

Modi, Shanu ;

Tokunaga, Eriko ;

Ito, Yoshinori ;

Iwata, Hiroji ;

Charif, Mahmoud ;

Lee, Caleb C. ;

Sugihara, Masahiro ;

Jikoh, Takahiro ;

Andre, Fabrice .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[28] Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study [J].

Rudin, Charles M. ;

Pietanza, M. Catherine ;

Bauer, Todd M. ;

Ready, Neal ;

Morgensztern, Daniel ;

Glisson, Bonnie S. ;

Byers, Lauren A. ;

Johnson, Melissa L. ;

Burris, Howard A., III ;

Robert, Francisco ;

Han, Tae H. ;

Bheddah, Sheila ;

Theiss, Noah ;

Watson, Sky ;

Mathur, Deepan ;

Vennapusa, Bharathi ;

Zayed, Hany ;

Lally, Satwant ;

Strickland, Donald K. ;

Govindan, Ramaswamy ;

Dylla, Scott J. ;

Peng, Stanford L. ;

Spigel, David R. .

LANCET ONCOLOGY, 2017, 18 (01) :42-51

[29] A FIRST IN-HUMAN, MULTICENTER, OPEN-LABEL, DOSE-FINDING PHASE 1 STUDY OF THE IMMUNE STIMULATOR ANTIBODY CONJUGATE NJH395 IN PATIENTS WITH NONBREAST HER2+ADVANCED MALIGNANCIES [J].

Janku, Filip ;

Han, Sae-Won ;

Doi, Toshihiko ;

Ajani, Jaffer ;

Kuboki, Yasutoshi ;

Mahling, Ping ;

Subramanian, Kulandayan ;

Pelletier, Marc ;

Askoxylakis, Vasileios ;

Siena, Salvatore .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 :A230-A230

[30] A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDY OF INCA32459, A BISPECIFIC ANTI-PD1 AND ANTI-LAG-3 ANTIBODY, IN PATIENTS WITH SELECT ADVANCED MALIGNANCIES [J].

Piha-Paul, Sarina ;

Bourayou, Nawel ;

Schaub, Richard ;

Yang, Yan-ou ;

Wei, Wendy ;

Mayes, Patrick ;

Gangadhar, Tara .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 :A756-A756

← 1 2 3 4 5 →